<?xml version="1.0" encoding="UTF-8"?><!-- generator="WordPress/2.8.2" -->
<rss version="0.92">
<channel>
	<title>Canadian Medicine</title>
	<link>http://www.canadianmedicine4all.com</link>
	<description></description>
	<lastBuildDate>Tue, 09 Mar 2010 18:28:41 +0000</lastBuildDate>
	<docs>http://backend.userland.com/rss092</docs>
	<language>en</language>
	
	<item>
		<title>Consumer Engagement</title>
		<description><![CDATA[
As many regular readers of P&#38;T know, I often scan the literature  of reports from the private sector and select some of these for my editorials. Recently, a report from the national BlueCross BlueShield Association (BCBSA) crossed my desk and appears to have important implications for P&#38;T committee members in different sectors.
Published at the end [...]]]></description>
		<link>http://www.canadianmedicine4all.com/consumer-engagement.html</link>
			</item>
	<item>
		<title>Lymphoma Research Foundation Workshop: Indolent Lymphoma</title>
		<description><![CDATA[
Indolent NHL is a slow-growing form of lymphoma. It encompasses what had been called low-grade NHL and some categories of intermediate-grade NHL. Depending on the type of cancer, patients today often live years without a lot of treatment. The usual strategy had been to wait until symptoms were manifested to a large degree before treatment [...]]]></description>
		<link>http://www.canadianmedicine4all.com/lymphoma-research-foundation-workshop-indolent-lymphoma.html</link>
			</item>
	<item>
		<title>Lymphoma Research Foundation Workshop: Emerging New Targets</title>
		<description><![CDATA[The practice of treating patients with relatively nonspecific cytotoxic compounds, such as chemotherapy, is now being complemented by a new era of targeted lymphoma drug development. Researchers are now able to identify a wide array of molecular targets and agents. The new agents include several broad classes of drugs that:

modulate or change the expression of [...]]]></description>
		<link>http://www.canadianmedicine4all.com/lymphoma-research-foundation-workshop-emerging-new-targets.html</link>
			</item>
	<item>
		<title>Lymphoma Research Foundation Workshop: TREATMENT</title>
		<description><![CDATA[Standard Therapy
At its most fundamental level, cancer has emerged as a disease of genes and DNA, and the entire message can now be interpreted with the aid of sophisticated techniques in molecular and cellular biology.
Rituximab-CHOP Chemotherapy
Aggressive chemotherapy may cure 50% of DLBCL cases; bone marrow transplantation might be able to rescue another 25%. Over the [...]]]></description>
		<link>http://www.canadianmedicine4all.com/lymphoma-research-foundation-workshop-treatment.html</link>
			</item>
</channel>
</rss>
